Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054661 · ClinicalTrials.gov registry record · NA
Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood
A NA study of G6PD Deficiency, sponsored by PATH.
- Completed
- Registry status
- NA
- Development phase
- 229
- Enrollment target
- 1
- Study location
NCT04054661 is a NA study of G6PD Deficiency that has completed, run by PATH. The registered enrollment target is 229 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04054661, a NA study of G6PD Deficiency, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- NA
- Development phase
- 229 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to assess the accuracy of the SD Biosensor STANDARD™ point-of-care (POC) G6PD test in measuring G6PD activity and classifying results compared to a reference assay and across repeated measurements in capillary samples.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SD Biosensor STANDARD G6PD Test
- DIAGNOSTIC_TEST Pointe Scientific Test Kit
- DIAGNOSTIC_TEST HemoCue System
Study Locations (1)
Pennsylvania
- BSC corporation - Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2020-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04054661
The ClinicalTrials.gov registry entry for NCT04054661 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with G6PD Deficiency appearing as the primary indexed condition, and to 3 interventions - of which SD Biosensor STANDARD G6PD Test is the first listed.
NCT04054661 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04054661 about?
NCT04054661 is a clinical study titled "Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood". The primary objective of the study is to assess the accuracy of the SD Biosensor STANDARD™ point-of-care (POC) G6PD test in measuring G6PD activity and classifying results compared to a reference assay and across repeated measurements in capillary samples.
What is the current status of trial NCT04054661?
This trial is currently completed. It is a NA study. The enrollment target is 229 participants. The study started on 2019-08-12. Estimated completion is 2020-01-31.
What conditions does trial NCT04054661 study?
This clinical trial studies the following conditions: G6PD Deficiency.
What interventions are being tested in trial NCT04054661?
The interventions under investigation include: SD Biosensor STANDARD G6PD Test (DIAGNOSTIC_TEST), Pointe Scientific Test Kit (DIAGNOSTIC_TEST), HemoCue System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04054661?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04054661 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for G6PD Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.